Drug Profile
Research programme: antibacterials - RiboNovix
Alternative Names: Antibacterial research programme - RiboNovixLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator RiboNovix
- Developer Wayne State University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 08 Oct 2004 Preclinical trials in Bacterial infections in USA (unspecified route)